Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$415K, compared with $405K a year earlier. Trailing-twelve-month other income / expenses was -$511K. Over 3 fiscal years it compounded at -44.8% a year.
Context
- Other income / expenses amounted to 0.9% of revenue in FY2025, down 10.0 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$415K or moves back toward the trailing-twelve-month quarterly average of -$127.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 309K USD
- Year-over-year change
- -89.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 309K | -89.9% |
| FY2024 | 2024-12-31 | 3.05M | -26.0% |
| FY2023 | 2023-12-31 | 4.13M | +124.7% |
| FY2022 | 2022-12-31 | 1.84M | +107.0% |
| FY2021 | 2021-12-31 | (26.2M) | — |
Other Income / Expenses vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 other income / expenses of -$511K is the 6th highest of the 9 companies compared; the peer median is $2.49M.
- Its year-over-year change of -120.4% is the 8th highest of 9, against a peer median of +9.4%.
- Other income / expenses amounts to 1.5% of revenue for RPID, versus a peer median of 56.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.95M | +197.9% | — | 79.6% | |
| LTM Mar 2026 | $23.26M | +14.4% | +3.1% | — | |
| LTM Mar 2026 | $4.47M | +17.7% | +46.1% | 7849.1% | |
| LTM Mar 2026 | $4.26M | +130.2% | — | 82.9% | |
| LTM Mar 2026 | $727K | -42.2% | -49.5% | — | |
| LTM Mar 2026 | -$511K | -120.4% | -44.8% | 1.5% | |
| LTM Mar 2026 | -$4.41M | +4.5% | — | 7.9% | |
| LTM Mar 2026 | -$5.84M | -0.6% | — | 8.1% | |
| LTM Mar 2026 | -$34.98M | -816.0% | — | 32.7% | |
| Peer median (excluding RPID) | $2.49M | +9.4% | +3.1% | 56.2% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | 30.97M | 25.67M | 28M | 28.16M | 25.98M |
| Gross Profit | (7.74M) | (8.54M) | (5.49M) | (109K) | 7.61M |
| Gross Margin | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| Research & Development | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M |
| Selling, General & Admin | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M |
| Operating Expenses | 39.49M | 54.68M | 51.08M | 49.81M | 55M |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| EBITDA | (69.25M) | (58.55M) | (49.33M) | (43.51M) | (42.74M) |
| EBITDA Margin | -298.1% | -341.7% | -219.1% | -155.1% | -127.3% |
| Operating Income | (47.23M) | (63.22M) | (56.56M) | (49.92M) | (47.39M) |
| Operating Margin | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| Interest Income | 0 | 1.78M | 4.21M | 3.16M | 1.51M |
| Interest Expense | 2.65M | 0 | 0 | 0 | 1.09M |
| Other Income / Expenses | (26.2M) | 1.84M | 4.13M | 3.05M | 309K |
| Income Before Tax | (73.43M) | (61.38M) | (52.44M) | (46.87M) | (47.08M) |
| Pre-Tax Margin | -316.1% | -358.3% | -232.9% | -167.1% | -140.2% |
| Income Tax Expense | 91K | (576K) | 31K | 22K | 40K |
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Net Margin | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| EPS (Basic) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| EPS (Diluted) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| Weighted Avg Shares | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
| Weighted Avg Shares (Diluted) | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.